Physician profile
Fay Woomer
NPI 1588609846
$1,171.86
in general payments reported to CMS, 2019-2025
26 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $140 · 2021: $109 · 2022: $178 · 2023: $208 · 2024: $208 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $250.59 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $112.29 | 2020-2024 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $78.48 | 2023-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $70.30 | 2021-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.05 | 2019 | |
| Abbott Laboratories | $62.38 | 2022-2025 | Freestyle Libre 3 |
| Amphastar Pharmaceuticals, INC. | $61.50 | 2023-2025 | Baqsimi |
| Insulet Corporation | $58.07 | 2023-2025 | Omnipod |
| Amarin Pharma, INC. | $56.38 | 2020-2023 | |
| Agile Therapeutics, INC. | $41.79 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $29.56 | 2020 | |
| Almatica Pharma LLC | $29.38 | 2022-2023 | Loreev Xr, Gralise |
| Avion Pharmaceuticals | $28.51 | 2020-2022 | |
| Hologic Sales and Service, LLC | $24.83 | 2023 | Aptima |
| Kowa Pharmaceuticals America, INC. | $24.21 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $23.79 | 2021 | |
| Dexcom, INC. | $19.97 | 2023 | Dexcom G6 Transmitter |
| Organon LLC | $17.05 | 2025 | Nexplanon |
| Meditrina | $17.00 | 2023 | |
| Glaxosmithkline, LLC. | $16.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.99 | 2021 | |
| Exeltis, USA INC. | $14.77 | 2024 | Slynd |
| Hikma Pharmaceuticals USA | $13.66 | 2020 | |
| Mayne Pharma Commercial LLC | $13.64 | 2021 | |
| Coopersurgical, INC. | $12.58 | 2022 | |
| Mannkind Corporation | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fay Woomer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.